Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Quick Facts
What This Study Found
EVX-01 elicited long-lasting T-cell responses in all five patients with no severe adverse events.
Key Numbers
How They Did This
The study involved an interim analysis of five patients receiving six administrations of the personalized vaccine, with tumor neoantigens identified using an AI platform.
Why This Research Matters
This research highlights the potential of personalized immunotherapy in treating melanoma, a challenging cancer type. The findings support further exploration of neoantigen vaccines in cancer treatment.
What This Study Doesn't Tell Us
The study is based on a small sample size and is an interim analysis, limiting the generalizability of the findings.
Trust & Context
- Original Title:
- Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
- Published In:
- Oncoimmunology, 11(1), 2023255 (2022)
- Authors:
- Mørk, Sofie Kirial, Kadivar, Mohammad, Bol, Kalijn Fredrike, Draghi, Arianna, Westergaard, Marie Christine Wulff, Skadborg, Signe Koggersbøl, Overgaard, Nana, Sørensen, Anders Bundgård, Rasmussen, Ida Svahn, Andreasen, Lars Vibe, Yde, Christina Westmose, Trolle, Thomas, Garde, Christian, Friis-Nielsen, Jens, Nørgaard, Nis, Christensen, Dennis, Kringelum, Jens Vindahl, Donia, Marco, Hadrup, Sine Reker, Svane, Inge Marie
- Database ID:
- RPEP-06386
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06386APA
Mørk, Sofie Kirial; Kadivar, Mohammad; Bol, Kalijn Fredrike; Draghi, Arianna; Westergaard, Marie Christine Wulff; Skadborg, Signe Koggersbøl; Overgaard, Nana; Sørensen, Anders Bundgård; Rasmussen, Ida Svahn; Andreasen, Lars Vibe; Yde, Christina Westmose; Trolle, Thomas; Garde, Christian; Friis-Nielsen, Jens; Nørgaard, Nis; Christensen, Dennis; Kringelum, Jens Vindahl; Donia, Marco; Hadrup, Sine Reker; Svane, Inge Marie. (2022). Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.. Oncoimmunology, 11(1), 2023255. https://doi.org/10.1080/2162402X.2021.2023255
MLA
Mørk, Sofie Kirial, et al. "Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.." Oncoimmunology, 2022. https://doi.org/10.1080/2162402X.2021.2023255
RethinkPeptides
RethinkPeptides Research Database. "Personalized therapy with peptide-based neoantigen vaccine (..." RPEP-06386. Retrieved from https://rethinkpeptides.com/research/mork-2022-personalized-therapy-with-peptidebased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.